Background: To evaluate the therapeutic effect of a single intravitreal injection of
bevacizumab for treatment of threshold retinopathy in retinopathy of prematurity (ROP) …

Background Despite increasing worldwide use of anti-vascular endothelial growth factor
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …

Background Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitors is
increasingly used to treat retinopathy of prematurity (ROP) in the absence of evidence about …

Purpose To evaluate vascular endothelial growth factor (VEGF) plasma levels before and
after intravitreal injection of ranibizumab in patients with retinopathy of prematurity (ROP) …

Purpose Intravitreal bevacizumab is increasingly used to treat severe retinopathy of
prematurity (ROP), but it enters the bloodstream, and there is concern that it may alter …

Purpose To describe a pattern of retinopathy of prematurity (ROP) disease regression and
chronic vascular arrest after intravitreal bevacizumab treatment that is not observed after …

Purpose To investigate the efficacy, safety, and anatomical outcomes associated with
intravitreal anti-vascular endothelial growth factor (VEGF) treatment of retinopathy of …

Purpose To report on the therapeutic effect of intravitreal low‐dose bevacizumab for
treatment for retinopathy of prematurity (ROP). Methods The single‐centre retrospective, non …

Aim To report serious adverse events and long-term outcomes of initial experience with
intraocular bevacizumab in retinopathy of prematurity (ROP). Methods Consecutive …

Objective Medium-and long-term sequelae of intravitreal bevacizumab (IVB) for type 1
retinopathy of prematurity (ROP) are uncertain. Our aim was to describe the fluorescein …